Researchers from the University of California and the Lawrence Berkeley National Laboratory have provided important new details about the activation of the epidermal growth factor receptor (EGFR). The receptor is a cell surface protein that has been strongly linked to a large number of cancers and is a major target for cancer therapies.
Jay Groves, one of the leaders of the research, says: "The more we understand about EGFR and the complex molecular machinery involved in the growth and proliferation of cells, the closer we will be to developing new and more effective ways to cure and treat the many different forms of cancer." Groves, who holds positions at both Berkeley Lab's Physical Biosciences Division and UC Berkeley's Chemistry Department, as well as the Howard Hughes Medical Institute, is one of two corresponding authors of a paper in the Journal Cell that describes the research. The other author is John Kuriyan, who also holds positions at Berkeley Lab, UC Berkeley and HHMI.
Once a protein that is coded for by genes has been assembled from amino acids, it may also need to be activated by post-translational processes, such as autophosphorylation in which phosphate is added. Protein activation can affect many important cellular processes including proliferation, differentiation and migration. Cancer is basically a case of these cellular functions gone wild, which often results from problems with the EGFR. However, despite its well-known links to cancer, EGFR activation is only partially understood.
As one of a group of receptors known as receptor tyrosine kinases, EGFR features a ligand-binding domain on its extracellular side and a kinase domain on its intracellular side. The explanation for EGFR activation is that the binding of the ligand, EGF, to its extracellular side induces dimerization of the receptor, the process in which two identical molecules combine to form a single compound molecule. This in turn brings together the kinase domains on the intracellular sides of the dimer, allowing them to phosphorylate one another. Groves believes that while this picture is accurate, it is an oversimplification of the mechanics behind the process because isolated intracellular kinase domains in solution can be active on their own at relatively low concentration, without EGF ligand-induced dimerization.
By measuring autophosphorylation as a function of EGFR, Groves, Kuriyan and their colleagues discovered that structural coupling between the EGFR transmembrane helix and extracellular juxtamembrane modules in addition to EGF ligand-engagement is required for EGFR activation. This structural coupling allows dimerization to take place in the presence of the EGF ligand.
With the mechanics behind EGFR activation now fully explained, Groves and his colleagues are now applying their techniques to another group of receptor tyrosine kinases, the Eph receptors, as well as T cell receptors that are so important to the immune system.
Jack
No comments:
Post a Comment